National Institute on Drug Abuse; Notice of Closed Meetings, 36826 [2024-09640]
Download as PDF
<![CDATA[
36826
Federal Register / Vol. 89, No. 87 / Friday, May 3, 2024 / Notices
meeting. Only one representative of an
organization will be allowed to present;
oral comments and presentations will be
limited to a maximum of 5 minutes.
Printed and electronic copies are
requested for the record. In addition,
any interested person may file written
comments with the Committee by
forwarding their statement to the
contact person listed on this notice. The
statement should include the name,
address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Because of time constraints for the
meeting, oral comments will be allowed
on a first-come, first-serve basis.
Members of the public who would
like to receive email notification about
future DMICC meetings should register
for the listserv available on the DMICC
website, https://www.niddk.nih.gov/
about-niddk/advisory-coordinatingcommittees/diabetes-mellitusinteragency-coordinating-committeedmicc?dkrd=lgdmn0022.
William T. Cefalu,
Director, Division of Diabetes, Endocrinology,
and Metabolic Diseases, National Institute of
Diabetes and Digestive and Kidney Diseases,
and Metabolic Diseases, National Institutes
of Health.
[FR Doc. 2024–09591 Filed 5–2–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
lotter on DSK11XQN23PROD with NOTICES1
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Analytical Chemistry and Stability Testing of
Treatment Drugs for Substance Use
Disorders.
Date: June 6, 2024.
VerDate Sep<11>2014
18:11 May 02, 2024
Jkt 262001
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sudhirkumar Udhavrao
Yanpallewar, M.D., Scientific Review Officer,
Scientific Review Branch, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 443–4577, sudhirkumar.yanpallewar@
nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; Seeking
Products to Address Social Needs Impacting
Substance Use Disorders (SUD).
Date: June 10, 2024.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute of Health,
National Institute on Drug Abuse, 301 North
Stonestreet Avenue, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Sindhu Kizhakke
Madathil, Ph.D., Scientific Review Officer,
Scientific Review Branch, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, 301 North Stonestreet
Avenue, MSC 6021, Bethesda, MD 20892,
(301) 827–5702, sindhu.kizhakkemadathil@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.277, Drug Abuse Scientist
Development Award for Clinicians, Scientist
Development Awards, and Research Scientist
Awards; 93.278, Drug Abuse National
Research Service Awards for Research
Training; 93.279, Drug Abuse and Addiction
Research Programs, National Institutes of
Health, HHS)
Dated: April 29, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–09640 Filed 5–2–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Library of Medicine; Notice of
Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Literature Selection
Technical Review Committee.
The meeting will be open to the
public as indicated below. Individuals
who plan to attend as well as those who
need special assistance, such as sign
language interpretation or other
reasonable accommodations, must
notify the Contact Person listed below
in advance of the meeting. The open
PO 00000
Frm 00078
Fmt 4703
Sfmt 4703
session will be videocast and can be
accessed from the NIH Videocasting and
Podcasting website (https://
videocast.nih.gov/).
The meeting is devoted to the review
and evaluation of journals for potential
indexing by the National Library of
Medicine and will be closed to the
public in accordance with the
provisions set forth in section
552b(c)(9)(B), Title 5 U.S.C., as
amended. Premature disclosure of the
titles of the journals as potential titles to
be indexed by the National Library of
Medicine, the discussions, and the
presence of individuals associated with
these publications could significantly
frustrate the review and evaluation of
individual journals.
Name of Committee: Literature Selection
Technical Review Committee.
Date: June 27–28, 2024.
Closed: June 27, 2024, 8:30 a.m. to 5:00
p.m.
Agenda: To review and evaluate journals
as potential titles to be indexed by the
National Library of Medicine.
Place: National Library of Medicine,
Building 38, Room 4S412, 8600 Rockville
Pike, Bethesda, MD 20892 (In-Person
Meeting).
Closed: June 28, 2024, 8:30 a.m. to 9:15
a.m.
Agenda: To review and evaluate journals
as potential titles to be indexed by the
National Library of Medicine.
Place: National Library of Medicine,
Building 38, Room 4S412, 8600 Rockville
Pike, Bethesda, MD 20892 (In-Person
Meeting).
Contact Person: Dianne Babski, Associate
Director, Division of Library Operations,
National Library of Medicine, 8600 Rockville
Pike, Bethesda, MD 20894, 301–827–4279,
babskid@mail.nih.gov.
Open: June 28, 2024, 9:15 a.m. to 10:30
a.m.
Agenda: NLM Directors’ Report.
Place: National Library of Medicine,
Building 38, Room 4S412, 8600 Rockville
Pike, Bethesda, MD 20892 (In-Person
Meeting).
Closed: June 28, 2024, 10:30 a.m. to 3:00
p.m.
Agenda: To review and evaluate journals
as potential titles to be indexed by the
National Library of Medicine.
Place: National Library of Medicine,
Building 38, Room 4S412, 8600 Rockville
Pike, Bethesda, MD 20892 (In-Person
Meeting).
In addition, any interested person may file
written comments with the committee by
forwarding their statement to the Contact
Person listed on this notice at least 10 days
in advance of the meeting.
Information is also available on the
Institute’s/Center’s home page: https://
www.nlm.nih.gov/medline/medline_about_
lstrc.html, where an agenda and any
additional information for the meeting will
be posted when available.
(Catalogue of Federal Domestic Assistance
Program No. 93.879, Medical Library
E:\FR\FM\03MYN1.SGM
03MYN1
]]>Agencies
[Federal Register Volume 89, Number 87 (Friday, May 3, 2024)]
[Notices]
[Page 36826]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-09640]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Analytical Chemistry and Stability Testing of
Treatment Drugs for Substance Use Disorders.
Date: June 6, 2024.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sudhirkumar Udhavrao Yanpallewar, M.D.,
Scientific Review Officer, Scientific Review Branch, Division of
Extramural Research, National Institute on Drug Abuse, NIH, 301
North Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 443-
4577, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Seeking Products to Address Social Needs Impacting
Substance Use Disorders (SUD).
Date: June 10, 2024.
Time: 9:30 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institute of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sindhu Kizhakke Madathil, Ph.D., Scientific
Review Officer, Scientific Review Branch, Division of Extramural
Research, National Institute on Drug Abuse, NIH, 301 North
Stonestreet Avenue, MSC 6021, Bethesda, MD 20892, (301) 827-5702,
[email protected].
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: April 29, 2024.
Lauren A. Fleck,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2024-09640 Filed 5-2-24; 8:45 am]
BILLING CODE 4140-01-P
